| Deal value | $125M |
|---|---|
| Share of market cap | 35.8% |
Key highlights
- Public offering of 25,000,000 shares priced at $5.00 per share
- Total gross proceeds of $125.0 million excluding underwriters' options
- Net proceeds estimated at $116.9 million after commissions and expenses
- Underwriters granted a 30-day option for 3,750,000 additional shares
- Closing of the offering scheduled for approximately November 13, 2026
What Is the Capital Raise?
PepGen Inc. has entered into a definitive underwriting agreement with Leerink Partners, Stifel, and Guggenheim Securities to issue 25 million shares of common stock. Priced at $5.00 per share, the offering represents a significant capital injection relative to the company's $349.1 million market capitalization. The agreement includes a 30-day overallotment option for underwriters to acquire an additional 3.75 million shares, which could bring total net proceeds to approximately $134.5 million. This financing follows a shelf registration statement on Form S-3 that was initially declared effective in May 2026, providing the company with streamlined access to public equity markets.
Down 16.9% since our story on 12 Nov: $5.04 when we broke it → $4.19 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $2.70 |
|---|---|
| 20 Oct | $2.87 |
| 21 Oct | $2.72 |
| 22 Oct | $2.70 |
| 23 Oct | $2.52 |
| 26 Oct | $2.49 |
| 27 Oct | $2.60 |
| 28 Oct | $2.53 |
| 29 Oct | $2.41 |
| 30 Oct | $2.36 |
| 2 Nov | $2.35 |
| 3 Nov | $2.46 |
| 4 Nov | $2.45 |
| 5 Nov | $2.32 |
| 6 Nov | $2.47 |
| 9 Nov | $2.39 |
| 10 Nov | $4.61 |
| 11 Nov | $5.26 |
| 12 Nov | $5.04 |
| 13 Nov | $4.36 |
| 16 Nov | $4.19 |
Use of Proceeds
- Advancement of the lead clinical candidate PGN-EDODM1 for myotonic dystrophy type 1
- Continued development of the proprietary Enhanced Delivery Oligonucleotide technology
- Support for ongoing clinical trials and associated research expenditures
- General corporate purposes and supplemental working capital requirements
- Expansion of the clinical-stage pipeline targeting rare genetic disorders
Business and Technical Context
The Boston-based clinical-stage biotechnology firm specializes in transforming the treatment landscape for rare genetic diseases. Its core competitive advantage lies in its EDO technology, which utilizes cell-penetrating peptides to maximize the uptake and biological activity of conjugated oligonucleotide therapeutics. The company's lead clinical candidate, PGN-EDODM1, is currently being evaluated for its ability to address the root cause of myotonic dystrophy type 1. This funding event signals a transition into more intensive clinical phases, requiring the bolstered balance sheet to sustain research and development activities through key data readouts and regulatory milestones.
Financial and Market Context
This capital raise occurs during a period of intense market activity for PEPG shares, which have recorded a 117.24% increase over the past week and a 101.6% rise over the last month. Despite the recent momentum, the Relative Strength Index of 78.8 indicates the stock has entered overbought territory technically. The offering price of $5.00 per share is positioned near the recent closing price of $5.04, reflecting high institutional demand for the equity placement. The transaction is expected to finalize by mid-November 2026, subject to customary closing conditions and final regulatory adherence following the initial launch on November 10.
| Share price | $5.04 |
|---|---|
| Market cap | $349M |
| 1-month price change | +101.60% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by PepGen Inc. announcing the pricing of a $125 million underwritten public offering of common stock.
Track PepGen Inc. live
Get the next PepGen Inc. SEC filing seconds after it lands.




